107 results
8-K
EX-99.1
RZLT
Rezolute Inc
14 Jun 24
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
4:51pm
Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future
424B5
RZLT
Rezolute Inc
14 Jun 24
Prospectus supplement for primary offering
4:49pm
strategy for tumor HI. The Division acknowledged the unmet need as well as the potential therapeutic benefit of RZ358 as demonstrated by the cases under
424B5
RZLT
Rezolute Inc
13 Jun 24
Prospectus supplement for primary offering
5:25pm
strategy for tumor HI. The Division acknowledged the unmet need as well as the potential therapeutic benefit of RZ358 as demonstrated by the cases under
8-K
EX-99.1
s1fkadsq
14 Sep 23
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
4:10pm
8-K
EX-14.1
usf30yh2ii51gcns8 2a
2 Jun 23
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:30pm
8-K
EX-99.1
16wa 0ugrc1x1k
15 Dec 22
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
4:54pm
8-K
EX-99.1
k01t6jssvah c6
9 Nov 22
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
4:12pm
8-K
EX-99.1
6rkr9
12 May 22
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
4:11pm